In order to rationalize the nutritional therapy of polytraumatized patients we have developed a concept to explain the humoral response and subsequent metabolic reactions to trauma, which is based on current reports in the literature and our own investigations. Three separate phases should be defined. a) The acute phase: catecholamines dominate in the initial phase following severe trauma. Insulin secretion is suppressed, and the levels of the anti-insulin hormones glucagon, cortisol and growth hormone are increased. Under modern conditions of treatment this phase lasts between 12-24 h. Nutritional therapy cannot be carried out during this phase of maximal glycogenolysis, lipolysis and gluconeogenesis because of the danger that a major metabolic imbalance might develop. b) The intermediate phase: This phase can be said to occur when after 12-24 h the primary stabilisation of the acute phase is complete. Insulin secretion can now be stimulated, but the levels of anti-insulin hormones remain high. This phase lasts for a number of days. The gradual introduction of nutritional therapy is now possible, but the danger of metabolic imbalances arising when abrupt substrate increases are made is nevertheless present. Should complications arise this phase can at any time revert to the acute phase. Patients who are only slightly injured or have undergone moderately extensive surgery are from the onset in this phase. c) The repair phase: In uncomplicated cases the intermediate phase passes after a number of days into the repair phase. This stage lasts for a number of weeks and is dominated by the presence of insulin. The levels of the anti-insulin hormones have returned to normal values.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source

Publication Analysis

Top Keywords

phase
14
nutritional therapy
12
acute phase
12
levels anti-insulin
12
anti-insulin hormones
12
insulin secretion
8
phase lasts
8
intermediate phase
8
lasts number
8
number days
8

Similar Publications

Scant Evidence for Long-Range Atmospheric Transport of Particle-Bound Benzotriazole Ultraviolet Stabilizers.

Environ Sci Technol

January 2025

Department of Physical and Environmental Sciences, University of Toronto Scarborough, 1265 Military Trail, Toronto, Ontario, Canada M1C 1A4.

Despite benzotriazole UV stabilizers (BT-UVs) being widely used since the 1960s, few empirical data on their atmospheric presence exist. UV-328 was added to the Stockholm Convention on Persistent Organic Pollutants, based in part on model calculations indicating atmospheric long-range transport potential. We investigated the atmospheric occurrence of BT-UVs at multiple sites that differ greatly in their proximity to potential sources.

View Article and Find Full Text PDF

The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).

View Article and Find Full Text PDF

MRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.

Blood

January 2025

Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.

The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.

View Article and Find Full Text PDF

Background: Opioid medications are important for pain management, but many patients progress to unsafe medication use. With few personalized and accessible behavioral treatment options to reduce potential opioid-related harm, new and innovative patient-centered approaches are urgently needed to fill this gap.

Objective: This study involved the first phase of co-designing a digital brief intervention to reduce the risk of opioid-related harm by investigating the lived experience of chronic noncancer pain (CNCP) in treatment-seeking patients, with a particular focus on opioid therapy experiences.

View Article and Find Full Text PDF

Background: Assisted partner services (APSs; sometimes called index testing) are now being brought to scale as a high-yield HIV testing strategy in many nations. However, the success of APSs is often hampered by low levels of partner elicitation. The Computer-Assisted Self-Interview (CASI)-Plus study sought to develop and test a mobile health (mHealth) tool to increase the elicitation of sexual and needle-sharing partners among persons with newly diagnosed HIV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!